The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility of text-based symptom monitoring of ovarian and endometrial patients during treatment.
Michelle Joy Naughton
No Relationships to Disclose
Ritu Salani
Honoraria - AstraZeneca; Clovis Oncology; Genmab; Johnson & Johnson; Tesaro
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
Juan Peng
No Relationships to Disclose
Floor Backes
Consulting or Advisory Role - Abbott (I); Agenus; Clovis Oncology; Merck; Tesaro
Research Funding - Clovis Oncology; Eisai; ImmunoGen
David M. O'Malley
Honoraria - Abbvie; Ambry Genetics; AstraZeneca; BioMedical Insights; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Marker Therapeutics; Myriad Genetics; Novocure; OncLive; OncoQuest; Prime Oncology; Targeted Oncology; Tesaro; Translational Genomics Research Institute
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Myriad Genetics; Novocure; OncoQuest; Tesaro; Translational Genomics Research Institute
Research Funding - Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Stem CentRx (Inst); Tesaro (Inst); TRACON Pharma (Inst); VentiRx (Inst)
David E. Cohn
Consulting or Advisory Role - Oncology Analytics
Research Funding - AbbVie (Inst); Advaxis (Inst); Agenus (Inst); Ajinomoto (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Henry Jackson Foundation (Inst); ImmunoGen (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen Research & Development (Inst); Ludwig Institute for Cancer Research (Inst); Novartis (Inst); NRG Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); PRA International (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tesaro (Inst); Tricon Pharmaceuticals (Inst)
Other Relationship - Elsevier; UpToDate
Kristin Leigh Bixel
No Relationships to Disclose
Cecilia DeGraffinreid
No Relationships to Disclose
Jennifer Moon
No Relationships to Disclose
Hibaq Loyan
No Relationships to Disclose
Electra D. Paskett
Stock and Other Ownership Interests - Meridian Bioscience Inc; Meridian Bioscience Inc (I); Pfizer; Pfizer (I)
Research Funding - Merck (Inst)